Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer
Ovarian cancer is one of the most lethal malignant gynecological tumors. More than 70% of patients with ovarian cancer are diagnosed at advanced stage. The 5-year survival in patients with advanced ovarian cancer is less than 30% because of the lack of effective biomarkers for diagnosis, prognosis,...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
China Anti-Cancer Association
2013-09-01
|
Series: | Cancer Biology & Medicine |
Subjects: | |
Online Access: | http://www.cancerbiomed.org/index.php/cocr/article/view/618 |
_version_ | 1819207083551096832 |
---|---|
author | Hong Zheng Jia-Yu Liu Feng-Ju Song Ke-Xin Chen |
author_facet | Hong Zheng Jia-Yu Liu Feng-Ju Song Ke-Xin Chen |
author_sort | Hong Zheng |
collection | DOAJ |
description | Ovarian cancer is one of the most lethal malignant gynecological tumors. More than 70% of patients with ovarian cancer are diagnosed at advanced stage. The 5-year survival in patients with advanced ovarian cancer is less than 30% because of the lack of effective biomarkers for diagnosis, prognosis, and personalized treatment. MicroRNA (miR) is a class of small noncoding RNAs that negatively regulate gene expression primarily through post-transcriptional repression. Many studies on tissue miR in ovarian cancer have been carried out and show great potential in clinical practice. However, tissue samples are not easily available because sampling causes injury. Researchers have started to focus on plasma/serum miR, assuming that blood samples may replace tissue samples in miR research in the future. Plasma/serum miR research is still in its early stages. Studies on its function in the early diagnosis of ovarian cancer have achieved some progress, but plasma/serum miR profiling for prognosis and personalized treatment of ovarian cancer remains unknown. A thorough understanding of the function of plasma/serum miR in ovarian cancer will facilitate early diagnosis and improve treatment for ovarian cancer. |
first_indexed | 2024-12-23T05:17:51Z |
format | Article |
id | doaj.art-b5a3cd580fb34907905683afff5683e7 |
institution | Directory Open Access Journal |
issn | 2095-3941 2095-3941 |
language | English |
last_indexed | 2024-12-23T05:17:51Z |
publishDate | 2013-09-01 |
publisher | China Anti-Cancer Association |
record_format | Article |
series | Cancer Biology & Medicine |
spelling | doaj.art-b5a3cd580fb34907905683afff5683e72022-12-21T17:58:46ZengChina Anti-Cancer AssociationCancer Biology & Medicine2095-39412095-39412013-09-0110312313010.7497/j.issn.2095-3941.2013.03.0012013030001Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancerHong Zheng0Jia-Yu Liu1Feng-Ju Song2Ke-Xin Chen3Department of Epidemiology and Biostatistics, Tianjin Medical University Cancer Hospital and Institute, National Clinical Research Center of Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin 300060, ChinaDepartment of Epidemiology and Biostatistics, Tianjin Medical University Cancer Hospital and Institute, National Clinical Research Center of Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin 300060, ChinaDepartment of Epidemiology and Biostatistics, Tianjin Medical University Cancer Hospital and Institute, National Clinical Research Center of Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin 300060, ChinaDepartment of Epidemiology and Biostatistics, Tianjin Medical University Cancer Hospital and Institute, National Clinical Research Center of Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin 300060, ChinaOvarian cancer is one of the most lethal malignant gynecological tumors. More than 70% of patients with ovarian cancer are diagnosed at advanced stage. The 5-year survival in patients with advanced ovarian cancer is less than 30% because of the lack of effective biomarkers for diagnosis, prognosis, and personalized treatment. MicroRNA (miR) is a class of small noncoding RNAs that negatively regulate gene expression primarily through post-transcriptional repression. Many studies on tissue miR in ovarian cancer have been carried out and show great potential in clinical practice. However, tissue samples are not easily available because sampling causes injury. Researchers have started to focus on plasma/serum miR, assuming that blood samples may replace tissue samples in miR research in the future. Plasma/serum miR research is still in its early stages. Studies on its function in the early diagnosis of ovarian cancer have achieved some progress, but plasma/serum miR profiling for prognosis and personalized treatment of ovarian cancer remains unknown. A thorough understanding of the function of plasma/serum miR in ovarian cancer will facilitate early diagnosis and improve treatment for ovarian cancer.http://www.cancerbiomed.org/index.php/cocr/article/view/618Ovarian neoplasmsmicroRNAsbiological markersearly diagnosis |
spellingShingle | Hong Zheng Jia-Yu Liu Feng-Ju Song Ke-Xin Chen Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer Cancer Biology & Medicine Ovarian neoplasms microRNAs biological markers early diagnosis |
title | Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer |
title_full | Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer |
title_fullStr | Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer |
title_full_unstemmed | Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer |
title_short | Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer |
title_sort | advances in circulating micrornas as diagnostic and prognostic markers for ovarian cancer |
topic | Ovarian neoplasms microRNAs biological markers early diagnosis |
url | http://www.cancerbiomed.org/index.php/cocr/article/view/618 |
work_keys_str_mv | AT hongzheng advancesincirculatingmicrornasasdiagnosticandprognosticmarkersforovariancancer AT jiayuliu advancesincirculatingmicrornasasdiagnosticandprognosticmarkersforovariancancer AT fengjusong advancesincirculatingmicrornasasdiagnosticandprognosticmarkersforovariancancer AT kexinchen advancesincirculatingmicrornasasdiagnosticandprognosticmarkersforovariancancer |